In concerted nationwide efforts to effectively battle opioid use disorder, Braeburn Pharmaceuticals will conduct a professional training session July 8-10 in Orlando, Florida, instructing practitioners on the use of Probuphine, its new six-month implant-based treatment plan.
Braeburn Pharmaceuticals is a “pill-free” company based in Princeton, New Jersey focused on neuroscience. The firm has embarked on a campaign to provide training for their product on a national level, with plans to repeat the event in several major metropolitan areas across the country, delivering a total of 262 sessions in 55 cities
"Braeburn is committed to making Probuphine available to patients in the Orlando area and across the country as soon as possible, which is why we're conducting training sessions so quickly after receiving FDA approval for Probuphine," Behshad Sheldon, Braeburn Pharmaceuticals’ president and CEO, said. "We look forward to educating qualified health care providers in Orlando on July 8, 9 and 10 on best practices for insertion and removal of Probuphine, the only treatment for opioid dependence that delivers medicine for up to six months. In the first four weekends, we certified 1,388 health care providers to provide the treatment to their patients."
The treatment must be administered by specially trained practitioners and is not available as a prescription. Over 5,000 health care providers have requested information on the new regimen to date.
47 Hulfish Street
Princeton, NJ 08542